← Back to Search

Corticosteroid

H.P. ACTHAR GEL for Vasculitis

Phase 4
Waitlist Available
Research Sponsored by Ocular Immunology and Uveitis Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day to 24 weeks
Awards & highlights

Study Summary

This trial will study the effects of Acthar on adults with a non-infectious form of eye inflammation.

Eligible Conditions
  • Vasculitis
  • Posterior Uveitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day to 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of responders to Acthar at the end of treatment.
Secondary outcome measures
Percentage of patients requiring rescue therapy.
Presence or absence of active retinal vasculitis at all other time points.
Safety assessments, including drug tolerability and adverse events; other ocular and/or systemic complications.

Trial Design

1Treatment groups
Experimental Treatment
Group I: H.P. ACTHAR GELExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Ocular Immunology and Uveitis FoundationLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025